INS and Alzheimer disease: Our data exhibited that patients receiving a higher cDDD of pioglitazone/insulin, pioglitazone alone, or insulin alone had higher risk of developing AD than those using a lower cDDD of pioglitazone/insulin, pioglitazone alone, or insulin alone, respectively.